纳米比亚乙型肝炎母婴传播预防的成本效果分析
该研究用马尔可夫模型评估纳米比亚四种HBV母婴传播预防策略的成本与健康产出。
要点
- 出生剂量疫苗联合靶向HBIG在纳米比亚具成本效果。
- 基于HBeAg序贯检测的母体抗病毒预防效果最优且具成本效果。
- 需低成本诊断检测以识别最受益于药物治疗的孕妇。
核心结论
- 联合主动与被动免疫及母体抗病毒预防可消除HBV母婴传播。
- 基于HBeAg序贯检测的母体抗病毒预防是效果最优的策略。
研究设计与样本
- 开发马尔可夫模型比较四种HBV母婴传播预防策略的成本与健康结局。
- 成本数据包括耗材、人力资源和医院设施,流行病学与转移概率等来自文献。
主要发现
- 出生剂量疫苗加靶向HBIG的ICER为1909.03美元/DALY。
- 基于HBeAg序贯检测的母体抗病毒预防ICER为2598.90美元/DALY。
关键数值与推荐
- 出生剂量疫苗加靶向HBIG的ICER为1909.03美元/DALY。
- 基于HBeAg序贯检测的母体抗病毒预防ICER为2598.90美元/DALY。
临床怎么用
- 在纳米比亚优先采用出生剂量疫苗联合靶向HBIG及基于HBeAg检测的母体抗病毒预防。
- 推动低成本诊断检测以识别最受益于抗病毒治疗的孕妇。
局限性
- 模型参数如流行病学与转移概率来自文献而非本地原始数据。
- 仅进行单因素敏感性分析检验模型稳健性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite access to a safe and effective vaccine, mother-to-child transmission (MTCT) of hepatitis B virus (HBV) persists in Africa. This is of concern since perinatally-infected infants are at highest risk of developing hepatocellular carcinoma, a life-threatening consequence of chronic HBV infection. While tools to prevent HBV MTCT are available, the cost implications of these interventions need consideration prior to implementation. A Markov model was developed to determine the costs and health outcomes of (1) universal HBV birth dose (BD) vaccination, (2) universal BD vaccination and targeted hepatitis B immunoglobulin (HBIG), (3) maternal antiviral prophylaxis using sequential HBV viral load testing added to HBV BD vaccination and HBIG, and (4) maternal antiviral prophylaxis using sequential HBeAg testing combined with HBV BD vaccination and HBIG. Health outcomes were assessed as the number of paediatric infections averted and disability-adjusted life years (DALYs) averted. Primary cost data included consumables, human resources, and hospital facilities. HBV epidemiology, transitions probabilities, disability weights, and the risks of HBV MTCT were extracted from the literature. Incremental cost-effectiveness ratios (ICERs) were calculated to compare successive more expensive interventions to the previous less expensive one. One-way sensitivity analyses were conducted to test the robustness of the model's outputs. At the Namibian cost/DALY averted threshold of US$3 142, the (1) BD vaccination + targeted HBIG, and (2) maternal antiviral prophylaxis with sequential HBeAg testing interventions were cost-effective. These interventions had ICERs equal to US$1909.03/DALY and US$2598.90/DALY averted, respectively. In terms of effectiveness, the maternal antiviral prophylaxis with sequential HBeAg testing intervention was the intervention of choice. The analysis showed that elimination of HBV MTCT is achievable using maternal antiviral prophylaxis with active and passive immunization. There is an urgent need for low cost diagnostic tests to identify those women who will most benefit from drug therapy to attain this laudable goal.
引用
- Tamandjou Tchuem CR, Andersson MI, Wiysonge CS, et al. Prevention of hepatitis B mother-to-child transmission in Namibia: A cost-effectiveness analysis. Vaccine. 2021. PMID: 33962836. doi:10.1016/j.vaccine.2021.04.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。